Evidence map›Paper›PMID 37497718›Full record

ArticleClinical and experimental rheumatology2023

The Collaborative National Quality and Efficacy Registry for Scleroderma: association of medication use on gastrointestinal tract symptoms in early disease and the importance of tobacco cessation.

Sarah Luebker, Tracy M Frech, Shervin Assassi, Jessica K Gordon, Elana J Bernstein, Virginia D Steen, Ami A Shah, Laura K Hummers, Carrie Richardson, Dinesh Khanna and 8 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and experimental rheumatology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 6 institutions in 1 country.

Sarah LuebkerVanderbilt University Medical Center, Division of Rheumatology and Immunology, Nashville, TN; and Tennessee Valley Health Care System, Veterans Affair Medical Center, Nashville, TN, USA.
Tracy M FrechVanderbilt University Medical Center, Division of Rheumatology and Immunology, Nashville, TN; and Tennessee Valley Health Care System, Veterans Affair Medical Center, Nashville, TN, USA.
Shervin AssassiUniversity of Texas Houston, Division of Rheumatology, Houston, TX, USA.
Jessica K GordonHospital for Special Surgery, Division of Rheumatology, New York City, NY, USA.
Elana J BernsteinDivision of Rheumatology, Department of Medicine, Columbia University Irving Medical Center, Vagelos College of Physicians and Surgeons, New York, NY, USA.
Virginia D SteenGeorgetown University Medical Center, Washington, DC, USA.
Ami A ShahJohns Hopkins University, Division of Rheumatology, Baltimore, MD, USA.
Laura K HummersJohns Hopkins University, Division of Rheumatology, Baltimore, MD, USA.
Carrie RichardsonNorthwestern University, Division of Rheumatology, Chicago, IL, USA.
Dinesh KhannaUniversity of Michigan, Division of Rheumatology, Ann Arbor, MI, USA.
Flavia V CastelinoHarvard University, Division of Rheumatology, Boston, MA, USA.
Lorinda ChungStanford University, Division of Rheumatology, Palo Alto, CA, USA.
Faye N HantMedical University of South Carolina, Division of Rheumatology, Charleston, SC, USA.
Victoria K ShanmugamGeorge Washington University, Division of Rheumatology, Washington, DC, USA.
John M VanBurenUniversity of Utah, Division of Paediatric Critical Care, Department of Paediatrics, Salt Lake City, UT, USA.
Jessica AlveyUniversity of Utah, Division of Paediatric Critical Care, Department of Paediatrics, Salt Lake City, UT, USA.
Monica HardingUniversity of Utah, Division of Paediatric Critical Care, Department of Paediatrics, Salt Lake City, UT, USA.
Nora SandorfiUniversity of Pennsylvania, Division of Rheumatology, Philadelphia, PA, USA. nora.sandorfi@pennmedicine.upenn.edu.
Vanderbilt University Medical Center · USColumbia University · USGeorgetown University · USMedical University of South Carolina · USUniversity of Michigan–Ann Arbor · USUniversity of Pennsylvania · US

Funding

Screening Chest CT to Detect Interstitial Lung Disease in Systemic SclerosisK23AR075112 · NIAMS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI BERNSTEIN, ELANA · 2019 to 2023
$794k
NIAMS NIH HHS K23 AR075112
6 · The paper itself

Abstract

objectivesSystemic Sclerosis (SSc) is frequently associated with gastrointestinal tract (GIT) involvement. The Collaborative National Quality and Efficacy Registry (CONQUER) is a US-based collaborative study collecting longitudinal follow up data on SSc patients with less than 5-years disease duration enrolled at Scleroderma centres of excellence. This manuscript presents the GIT natural history and outcomes in relation to other scleroderma manifestations and medication exposures.

methodsCONQUER participants that had completed a minimum of two serial Scleroderma Clinical Trials Consortium GIT Questionnaires (GIT 2.0) were included in this analysis. Patients were categorised by total GIT 2.0 severity at baseline, and by category change: none-to-mild (0.49); moderate (0.50-1.00), and severe-to-very severe (1.01-3.00) at the subsequent visit. Based on this data, four groups were identified: none-to-mild with no change, moderate-to-severe with no change, improvement, or worsening. Clinical features and medications, categorised as gastrointestinal tract targeted therapy, anti-fibrotic, immunosuppression, or immunomodulatory drugs, were recorded. Analysis included a proportional odds modelaccounting for linear and mixed effects of described variables.

results415 enrolled CONQUER participants met project inclusion criteria. Most participants had stable mild GIT symptoms at baseline and were on immunomodulatory and anti-reflux therapy. In most patients, anti-reflux medication and immunosuppression initiation preceded the baseline visit, whereas anti-fibrotic initiation occurred at or after the baseline visit. In the proportional odds model, worsening GIT score at the follow-up visit was associated with current tobacco use (odds ratio: 3.48 (1.22, 9.98, p 0.020).

conclusionsThis report from the CONQUER cohort, suggests that most patients with early SSc have stable and mild GIT disease. Closer follow-up was associated with milder, stable GIT symptoms. There was no clear association between immunosuppression or anti-fibrotic use and severity of GIT symptoms. However, active tobacco use was associated with worse GIT symptoms, highlighting the importance of smoking cessation counselling in this population.

Indexed as

Gastroesophageal RefluxGastrointestinal DiseasesScleroderma, LocalizedScleroderma, SystemicTobacco Use CessationHumansQuality of LifeRegistries

Identifiers

PMID37497718
PMCPMC13336142
OpenAlexW4385272027

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.